Genetic, Biomarker and Biospecimen Core

遗传、生物标志物和生物样本核心

• 批准号: 10264436
• 负责人: TATIANA M. FOROUD
• 金额: $ 35.18万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264436
• 关键词: Address; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease related dementia; Alzheimer' s disease therapeutic; Amyloid beta-42; Amyloid beta-Protein; Animal Model; Area; Astrocytes; Basic Science; Behavioral; Biological Markers; Blood specimen; Clinical; Cognitive; Collaborations; Collection; Computerized Medical Record; DNA; Data; Dementia; Development; Disease; Disease susceptibility; Education; Fostering; Generations; Genetic; Genetic Counseling; Genetic Markers; Genomics; Genotype; Goals; Home; Image; Impaired cognition; Indiana; Individual; Inherited; Lead; Link; Liquid substance; Mentors; Microglia; Mission; Molecular Genetics; Multimodal Imaging; Neurons; Neurosciences Research; Outcome; Participant; Peripheral Blood Mononuclear Cell; Plasma; Play; RNA; Recording of previous events; Research; Research Institute; Research Personnel; Resources; Risk Factors; Role; Sampling; Specimen; Testing; Therapeutic; Universities; Visit; Work; blood-based biomarker; causal variant; clinical predictors; cohort; drug development; drug discovery; genome wide association study; genomic data; imaging genetics; induced pluripotent stem cell; innovation; interest; lectures; medical schools; meetings; member; mild cognitive impairment; molecular imaging; mouse model; neuroimaging; normal aging; novel therapeutics; patient population; pre-clinical; programs; protective factors; research study; specific biomarkers; stem cell differentiation; symptom treatment; tau Proteins; therapeutic evaluation; translational study

Project Summary – Genetics, Biomarker, and Biospecimen Core (GBBC) The Indiana Alzheimer’s Disease Research Center (IADRC) has a strong history of innovative research in molecular and imaging genomics and will continue to focus on the role of genetics and other types of biomarkers as predictors of clinical trajectories among the broader group of individuals with Alzheimer’s disease (AD) and other dementias, as well as those in preclinical and prodromal stages, such as subjective cognitive decline (SCI) and mild cognitive impairment (MCI). The Genetics, Biomarker and Biospecimen Core (GBBC) plays a central role in supporting this overall focus through the collection of uniform biospecimens, coordination of genetic data and generation of blood-based biomarkers. The GBBC also supports multiple national efforts through the broad sharing of specimens and data. The GBBC leverages the unique patient populations and genomics resources at Indiana University School of Medicine to support each Core as well as the overall goals of the IADRC. The GBBC fosters new research directions through the common banking of samples from diverse research groups. These samples are then available to address research questions that are central to the interests of the IADRC. In addition, these samples are available for collaborative studies, thereby enhancing the power of all ADRC studies focused on disease susceptibility, onset and progression. In this application, the GBBC will expand its scope to also support functional studies through the targeted development of induced pluripotent stem cells (iPSCs). The GBBC will leverage both the IUSM-JAX-Pitt MODEL-AD Center, whose goal is to develop, characterize and test therapeutic strategies in mouse models of AD and the IUSM-Purdue TREAT AD Center, whose goal is to integrate sophisticated capabilities for early drug discovery, to contribute to a broader study of AD target hypotheses (beyond Aβ) to generate new classes of potential therapeutics. The IADRC GBBC proposes the following specific aims: 1. Obtain longitudinal biospecimen samples from all subjects seen in the Clinical Core and support local and national research studies. 2. Obtain biomarker data to support ongoing studies of cognitive impairment and dementia. 3. Establish iPSCs from select IADRC participants to support local research studies. 4. Provide education in the areas of genetics and biomarkers.

项目摘要-遗传学、生物标志物和生物标本核心（GBBC） 印第安纳州阿尔茨海默病研究中心（IADRC）在创新方面有着悠久的历史， 分子和成像基因组学的研究，并将继续关注遗传学的作用 和其他类型的生物标志物作为更广泛的人群中临床轨迹的预测因子， 患有阿尔茨海默病（AD）和其他痴呆的个体，以及临床前痴呆的个体， 和前驱期，如主观认知下降（SCI）和轻度认知障碍 （MCI）。遗传学、生物标志物和生物标本核心（GBBC）在以下方面发挥着核心作用： 通过收集统一的生物标本，协调 基因数据和基于血液的生物标志物的生成。GBBC还支持多个 通过广泛分享标本和数据，加强各国的努力。 GBBC利用印第安纳州独特的患者群体和基因组学资源 大学医学院，以支持每个核心以及IADRC的总体目标。 GBBC通过以下样本的共同库来促进新的研究方向： 不同的研究小组。这些样本可用于解决研究问题， 对IADRC的利益至关重要。此外，这些样品可用于 合作研究，从而提高所有ADRC研究的力量集中在疾病 易感性、发病和进展。 在此应用中，GBBC将扩大其范围，通过 诱导多能干细胞（iPSC）的靶向开发。GBBC将利用这两个 IUSM-JAX-Pitt MODEL-AD中心，其目标是开发、表征和测试 AD小鼠模型和IUSM-Purdue TREAT AD中心的治疗策略， 目标是整合早期药物发现的先进能力，为更广泛的 研究AD靶向假设（超越Aβ），以产生新的潜在治疗方法。 IADRC GBBC提出了以下具体目标： 1.从临床核心中观察到的所有受试者中获得纵向生物标本样本， 支持地方和国家研究。 2.获取生物标志物数据，以支持正在进行的认知障碍和痴呆症研究。 3.从选定的IADRC参与者中建立iPSC，以支持当地的研究。 4.提供遗传学和生物标志物领域的教育。